<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25073">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780349</url>
  </required_header>
  <id_info>
    <org_study_id>CL-003</org_study_id>
    <nct_id>NCT02780349</nct_id>
  </id_info>
  <brief_title>Evaluation of WIRION™ EPS in Lower Extremities Arteries</brief_title>
  <acronym>WISE LE</acronym>
  <official_title>Evaluation of WIRION™ EPS in Lower Extremities Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gardia Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gardia Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the safety and performance of the WIRION™ EPS in subjects undergoing lower
      extremity atherectomy for the treatment of Peripheral Arterial Disease (PAD)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from major adverse events (MAE) to 30 days post procedure.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">153</enrollment>
  <condition>Peripheral Arterial Disease (PAD)</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WIRION</intervention_name>
    <description>Embolic Protection System</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is at least 18 years of age

          2. Subject or authorized representative, signed a written Informed Consent form to
             participate in the study, prior to any study related procedures

          3. Subject is willing to comply with the protocol requirements and return to the
             treatment center for all required clinical evaluations

          4. Rutherford classification 2-4

          5. Has moderate to severe calcification visualized on angiogram in the femoropopliteal
             arteries

          6. Planned atherectomy of the native femoropopliteal arteries

          7. Reference vessel diameter for intended filter location must be visually estimated to
             be ≥3.5mm and ≤6.0mm

          8. An adequate &quot;landing zone&quot; for placement of the WIRION™ device distal to the target
             lesion of at least 30mm

          9. A female subject is eligible if not of child bearing potential or has a negative
             pregnancy test within the previous 7 days and agrees to remain on birth control
             throughout the study

        Exclusion Criteria:

          1. Any planned surgical or endovascular intervention within 30 days before or after the
             index procedure

          2. A lesion deemed not accessible by the WIRION™ EPS

          3. Inability to take aspirin or ADP receptor antagonists

          4. History of bleeding diathesis or coagulopathy or will refuse blood transfusion if
             deemed necessary

          5. Has perforation, dissection, or other injury of the access or target vessel requiring
             additional stenting or surgical intervention before enrollment

          6. Subject is enrolled in another drug or device study protocol that has not reached its
             primary endpoint (participating in registry studies is not excluded)

          7. Life expectancy less than 12 months

          8. Known severe renal insufficiency (eGFR &lt;30 ml/min/1.72m2).

          9. ≤1-vessel tibial run-off status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Unity Point</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Christensen, RN</last_name>
      <email>christensenl@mcrfmd.com</email>
    </contact>
    <investigator>
      <last_name>Nicolas Shammas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shannon Williams</last_name>
      <email>slwilliams@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>James Jenkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Daltom</last_name>
      <email>keb2114@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Pucillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>August 3, 2016</lastchanged_date>
  <firstreceived_date>May 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
